企業プロフィール
Viatris Inc. 株価・ニュース・カタリスト
- ティッカー:
- VTRS
- 取引所:
- NASDAQ
- セクター:
- Generics, Small Molecule Drugs
- 所在地:
- United States
株価パフォーマンス
17.46 USD (-1.47%)
終値
最終更新: 2026年10月1日
18.3B USD
時価総額
株価変動の要因
2026年10月1日 時点で VTRS は 1.47% 下落し、$17.46 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Global Medicines Company
Viatris is a global healthcare company that develops, manufactures, and commercializes branded medicines, generic drugs, complex products, and biosimilars. Its portfolio is distributed across developed and emerging markets through a broad manufacturing, regulatory, and commercial network.
Established Brands Portfolio
The company's established brands include medicines used in cardiovascular disease, central nervous system disorders, respiratory disease, infectious disease, and other chronic conditions. These products often rely on geographic expansion, lifecycle management, and durable physician familiarity rather than exclusively on new molecular innovation.
Generics and Complex Products
Viatris manufactures oral solids, injectables, transdermal products, respiratory medicines, and other technically complex dosage forms. Scale in development, manufacturing, and regulatory submissions allows the company to supply a wide range of affordable medicines across multiple regions.
Biosimilars Business
The biosimilars portfolio gives Viatris exposure to large biologic markets through products referencing established therapies in oncology, immunology, diabetes, and other specialties. Commercialization is frequently conducted through regional partnerships that divide development, manufacturing, and market responsibilities.
Pipeline and Portfolio Management
Viatris combines internal development with licensing, partnerships, acquisitions, and divestitures to reshape its portfolio. New products include Gwyn Lo, while MR-107A-02 is being developed as a fast-acting, non-opioid meloxicam formulation for moderate-to-severe acute pain.
今後のカタリスト
- Commercial availability of Gwyn Lo later in 2026.
- FDA PDUFA decision for MR-107A-02 in moderate-to-severe acute pain on December 27, 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。